This new molecule causes in HER expressed breast, ovarian and gastric cancers, a longer lasting response and also inhibiting tumor growth increasing the progression free survival in comparison with trastuzumab
PharmaMar (MCE: PHM) has announced the positive results of MI130004, a novel antibody conjugate combining trastuzumab with PM050489, a molecule of marine origin. The company has analyzed its antitumor activity in different tumor cell lines (breast, ovarian and gastric cancers) that express different levels of HER2 in both in vitro and in vivo tests.
The results published by the prestigious magazine Molecular Cancer Therapeutics, from the American Association for Cancer Research (AACR), (http://mct.aacrjournals.org/content/early/2018/02/13/1535-7163.MCT-17-0795) show that this new molecule provokes in tumors that express HER2 a longer lasting response and inhibits significantly tumor growth providing a higher median progression free survival time in comparison with trastuzumab.
MI130004 is the result of the research carried out by PharmaMar to identify and synthesize molecules of a marine origin for their use as active agents in antibody-drug conjugates, as is the case with PM050489.
As a Company, PharmaMar is positioning itself as a supplier of cytotoxic products that are necessary for companies specialized in the antibody-drug conjugate technology.
Contacts: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914-44-45-00)
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today announced its participation in the 'Runes Incubator.' This program, initiated by OnePiece Labs and supported by Merlin Chain and Franklin Templeton,...
SK hynix Inc. (or "the company", www.skhynix.com) announced today that it has recently signed a memorandum of understanding with TSMC for collaboration to...
ShipSaving, a fast-growing shipping platform recognized in the 2023 Deloitte Technology Fast 500tm, proudly announces a groundbreaking development as the first multi-carrier shipping company to offer UPS no-label shipping. This innovative feature...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...
In celebration of Miami Tech Month, the city of Miami is hosting a variety of events, welcoming venture capitalists, entrepreneurs, and technology innovators from around the globe. During this week, the city hosted Startup OLÉ, one of Europe's...
Skyhigh Security today announced it was named a Visionary in the 2024 Gartner® Magic Quadranttm for the second year in a row for its Security Service Edge (SSE) portfolio. The Magic Quadrant evaluates vendors based on their Ability to Execute and...